Tauns Laboratories, Inc. (197A) Price & Analysis

197A Stock Chart & Stats

¥491.00-¥1.00(-0.20%)

At close: Oct 30 4:00 PM EDT

Day’s Range: JPY 488.00 - JPY 495.00
52-Week Range: JPY 463.00 - JPY 577.00
Previous Close: JPY 492.00
Volume: 864.10K
Average Volume (3M): 156.66K
Market Cap: JPY 52.45B
Enterprise Value: JPY 68.50B
Total Cash (Recent Filing): JPY 3.56B
Total Debt (Recent Filing): JPY 21.26B
Price to Earnings (P/E): 9.4
Beta: 0.39
Next Earnings: Nov 12, 2026
EPS Estimate: N/A
Next Dividend Ex-Date: Dec 29, 2026
Dividend Yield: 5.70%

Bulls Say, Bears Say

Bulls Say

Strong Profitability

Sustained gross and operating profitability, together with a substantially higher net margin, indicates strong earnings capacity. This provides internal funding potential and resilience, although operating-margin trends should continue to be monitored.

High Return On Equity

High returns generated on shareholder capital indicate that the company has historically converted its equity base into meaningful profits. This supports capital efficiency and can strengthen long-term value creation if leverage remains controlled.

Positive Asset Growth

Positive asset growth suggests the company is expanding its operating or resource base rather than experiencing balance-sheet contraction. This may support future capacity and development, provided growth is matched by sustainable cash generation.

Bears Say

Volatile Cash Generation

Repeated swings between positive and negative operating cash flow weaken earnings quality and make funding needs harder to predict. If volatility persists, the company may rely more heavily on debt or working-capital management.

Rising Leverage

The sharp increase in debt and debt-to-equity above 1.0 reduce financial flexibility. Higher leverage increases sensitivity to earnings or cash-flow weakness and can constrain investment capacity if funding conditions deteriorate.

Uneven Revenue And Margin Trends

Uneven revenue performance indicates demand may be volatile, while recent operating-margin compression raises questions about profit durability. Sustained growth and margin recovery are needed to demonstrate that strong net income can persist.

Tauns Laboratories, Inc. News

Tauns Laboratories to Expand Business Scope and Overhaul Governance Structure

The latest announcement is out from Tauns Laboratories, Inc. ( ($JP:197A) ). Tauns Laboratories, Inc. plans to amend its Articles of Incorporation to broaden its stated business scope and restructure

2M ago197A

Tauns Laboratories Overhauls Governance With New Audit and Supervisory Committee Structure

Tauns Laboratories, Inc. ( ($JP:197A) ) just unveiled an update. Tauns Laboratories, Inc. plans to transition from a traditional Board of Corporate Auditors structure to a Company with an Audit

2M ago197A

Tauns Laboratories’ Profit Slides on Lower Sales as Cash Flow Turns Negative

Tauns Laboratories, Inc. ( ($JP:197A) ) has issued an announcement. Tauns Laboratories reported FY2026 net sales of ¥14.37 billion, down 22.9% year on year, with operating income halving to ¥4.20

2M ago197A

Tauns Laboratories Books ¥3.9 Billion Government Subsidy as Special Gain

An announcement from Tauns Laboratories, Inc. ( ($JP:197A) ) is now available. Tauns Laboratories has booked a special gain of ¥3,949 million in the fourth quarter of the fiscal year

2M ago197A

Tauns Laboratories Corrects Presentation of Operating Income Forecast Without Changing Outlook

Tauns Laboratories, Inc. ( ($JP:197A) ) has shared an update. Tauns Laboratories has issued a correction to its recently updated mid-term management plan, clarifying the way it presents its full-year

3M ago197A

Tauns Laboratories Revamps Mid-Term Plan With Strong Growth Targets

Tauns Laboratories, Inc. ( ($JP:197A) ) has issued an update. Tauns Laboratories has updated its mid-term management plan, shifting the covered period to the fiscal years ending June 2027 through

3M ago197A

Tauns Laboratories Posts Sharp Earnings Drop but Holds Forecast and Dividend

Tauns Laboratories, Inc. ( ($JP:197A) ) has shared an announcement. Tauns Laboratories reported a sharp contraction in performance for the nine months ended March 31, 2026, with net sales falling

5M ago197A

Tauns Laboratories Slashes Full-Year Forecast as Infection Waves Ease

Tauns Laboratories, Inc. ( ($JP:197A) ) has issued an update. Tauns Laboratories has sharply revised down its earnings forecast for the fiscal year ending June 30, 2026, cutting projected net

7M ago197A

Tauns Laboratories Issues FY2026 Q2 Financial Highlights

The latest update is out from Tauns Laboratories, Inc. ( ($JP:197A) ). Tauns Laboratories, Inc. has released a financial highlights document for the second quarter of FY2026, covering the period

8M ago197A

Tauns Laboratories Profit Halves on Lower Sales but Keeps Full-Year Outlook and Dividend Plan

Tauns Laboratories, Inc. ( ($JP:197A) ) just unveiled an announcement. Tauns Laboratories reported a sharp year-on-year decline for the six months ended December 31, 2025, with net sales down 30.9%

8M ago197A

197A FAQ

What was Tauns Laboratories, Inc.’s price range in the past 12 months?

Tauns Laboratories, Inc. lowest stock price was ¥463.00 and its highest was ¥577.00 in the past 12 months.

What is Tauns Laboratories, Inc.’s market cap?

Tauns Laboratories, Inc.’s market cap is ¥52.45B.

When is Tauns Laboratories, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Tauns Laboratories, Inc.’s earnings last quarter?

Tauns Laboratories, Inc. released its earnings results on Aug 13, 2026. The company reported ¥28.92 earnings per share for the quarter.

Is Tauns Laboratories, Inc. overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Tauns Laboratories, Inc. pay dividends?

Tauns Laboratories, Inc. pays a Annually dividend of ¥14.5 which represents an annual dividend yield of 5.7%. See more information on Tauns Laboratories, Inc. dividends here

What is Tauns Laboratories, Inc.’s EPS estimate?

Tauns Laboratories, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tauns Laboratories, Inc. have?

Tauns Laboratories, Inc. has 106,813,095 shares outstanding.

What happened to Tauns Laboratories, Inc.’s price movement after its last earnings report?

Tauns Laboratories, Inc. reported an EPS of ¥28.92 in its last earnings report. Following the earnings report the stock price went down -0.416%.

Which hedge fund is a major shareholder of Tauns Laboratories, Inc.?

Currently, no hedge funds are holding shares in JP:197A

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description